WHY BENLYSTA?

Dr. William Pendergraft, Nephrologist

Paid consultant to GSK at the time of filming.

  • TRANSCRIPT

    DR. PENDERGRAFT: My name is Doctor Will Pendergraft. I’m a practicing nephrologist in Chapel Hill, North Carolina.

    ON-SCREEN TEXT: Dr. William Pendergraft, Nephrologist
    Paid consultant to GSK at the time of filming.

    ON-SCREEN TEXT: “Why BENLYSTA?”
    Stay tuned for Important Product Information

    DR. PENDERGRAFT: One of the most common questions I get from my colleagues who are nephrologists is when and where and how can we use BENLYSTA in patients with lupus nephritis?

    DR. PENDERGRAFT: I think what’s nice is we have data from the BLISS lupus nephritis trial, which for me was a very real-world trial that allowed us to use one of two different remission-induction regimens. Either the ALMS protocol with mycophenolate or Euro-lupus protocol using cyclophosphamide. For us as nephrologists, it’s nice to be able to get to pick one of those two regimens and to know that BENLYSTA can be used at the same time.

    ON-SCREEN TEXT: “… two different remission-induction regimens”

    DR. PENDERGRAFT: And, for me, I think what the BLISS lupus nephritis trial showed was that BENLYSTA is really a new member in the toolkit of our armamentarium for remission-induction and maintenance therapy. Clearly, we can’t use it in every patient, but the BLISS lupus nephritis trial incorporated the remission-induction and maintenance periods, which means there is a wide window in which we can use BENLYSTA in both of those periods.

    ON-SCREEN TEXT: “BENLYSTA is a new member in the toolkit”

    ON-SCREEN TEXT: “Induction and maintenance”

    DR. PENDERGRAFT: Thank you for watching. Visit the BENLYSTA website for more information.

    ON-SCREEN TEXT: BENLYSTAHCP.com

    VOICEOVER:

    IMPORTANT PRODUCT INFORMATION

    For patients on standard therapy: Aged 5 years and older with active systemic lupus erythematosus or active lupus nephritis. Not for use in severe active central nervous system lupus. Reported: serious & sometimes fatal infections; progressive multifocal leukoencephalopathy; acute hypersensitivity reactions, including anaphylaxis & death, and infusion-related reactions; and, depression & suicidality. Avoid live vaccines. Common adverse reactions: nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, pharyngitis, & injection site reactions.

    ON-SCREEN TEXT:

    IMPORTANT PRODUCT INFORMATION

    For patients on standard therapy: Aged 5+ and older with active systemic lupus erythematosus or active lupus nephritis. Not for use in severe active CNS lupus. Reported: serious & sometimes fatal infections; PML; acute hypersensitivity reactions, including anaphylaxis & death, and infusion-related reactions; and, depression & suicidality. Avoid live vaccines. Common adverse reactions: nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, pharyngitis, & injection site reactions.

    Please see additional Important Safety Information and full Prescribing Information, including Medication Guide, on the BENLYSTAHCP.com website.

    ON-SCREEN TEXT:
    BENLYSTA
    (belimumab)
    Intravenous Use 120 mg/vial
    Subcutaneous Use 200 mg/mL

    GSK Logo

    Trademarks are owned by or licensed to the GSK group of companies.
    ©2022 GSK or licensor. BELVID220047 August 2022 Produced in USA.

You may also like

WHY BENLYSTA?

Dr. Alvin Wells, Rheumatologist

WHY BENLYSTA?

Dr. Grace Wright, Rheumatologist

JOIN US FOR
A LIVE WEBINAR

Paid consultants to GSK at the time of filming.